Updated findings on low-risk MINDACT participants reported

Laura van 't Veer discusses the latest data from the MINDACT trial of adjuvant chemotherapy de-escalation in hormone receptor-positive early breast cancer and puts the results in the context of the RxPONDER and TAILORx findings.